Lessons Learned from the Transgenic Huntington's Disease Rats

被引:6
|
作者
Vlamings, Rinske [1 ]
Zeef, Dagmar H. [1 ]
Janssen, Marcus L. F. [1 ,2 ]
Oosterloo, Mayke [2 ]
Schaper, Frederic [1 ]
Jahanshahi, Ali [1 ]
Temel, Yasin [1 ,3 ]
机构
[1] Maastricht Univ, Med Ctr, Dept Neurosci, NL-6229 ER Maastricht, Netherlands
[2] Maastricht Univ, Dept Neurol, Med Ctr, NL-6202 AZ Maastricht, Netherlands
[3] Maastricht Univ, Dept Neurosurg, Med Ctr, NL-6202 AZ Maastricht, Netherlands
关键词
SUBTHALAMIC NUCLEUS STIMULATION; DEEP BRAIN-STIMULATION; GLOBUS-PALLIDUS NETWORK; CAG REPEAT LENGTH; PARKINSONS-DISEASE; SUBSTANTIA-NIGRA; SYNAPTIC PLASTICITY; PERIRHINAL CORTEX; BASAL GANGLIA; MOUSE MODELS;
D O I
10.1155/2012/682712
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Huntington's disease (HD) is a fatal inherited disorder leading to selective neurodegeneration and neuropsychiatric symptoms. Currently, there is no treatment to slow down or to stop the disease. There is also no therapy to effectively reduce the symptoms. In the investigation of novel therapies, different animal models of Huntington's disease, varying from insects to nonhuman primates, have been created and used. Few years ago, the first transgenic rat model of HD, carrying a truncated huntingtin cDNA fragment with 51 CAG repeats under control of the native rat huntingtin promoter, was introduced. We have been using this animal model in our research and review here our experience with the behavioural, neurophysiological, and histopathological phenotype of the transgenic Huntington's disease rats with relevant literature.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Experimental therapeutics in transgenic mouse models of Huntington's disease
    Beal, MF
    Ferrante, RJ
    NATURE REVIEWS NEUROSCIENCE, 2004, 5 (05) : 373 - 384
  • [42] Dantrolene is neuroprotective in Huntington's disease transgenic mouse model
    Chen, Xi
    Wu, Jun
    Lvovskaya, Svetlana
    Herndon, Emily
    Supnet, Charlene
    Bezprozvanny, Ilya
    MOLECULAR NEURODEGENERATION, 2011, 6
  • [43] Effect of luteolin on the transgenic Drosophila model of Huntington's disease
    Siddique, Yasir Hasan
    Rahul, Himanshi
    Varshney, Himanshi
    Mantasha, I
    Shahid, M.
    COMPUTATIONAL TOXICOLOGY, 2021, 17
  • [44] Transgenic model for the study of oxidative damage in Huntington's disease
    Segovia, J
    REDOX CELL BIOLOGY AND GENETICS, PT B, 2002, 353 : 365 - 373
  • [45] Progress in developing transgenic monkey model for Huntington’s disease
    Brooke R. Snyder
    Anthony W. S. Chan
    Journal of Neural Transmission, 2018, 125 : 401 - 417
  • [46] Metabolic and glutamatergic disturbances in the Huntington's disease transgenic mouse
    Higgins, DS
    Hoyt, KR
    Baic, C
    Vensel, J
    Sulka, M
    OXIDATIVE/ENERGY METABOLISM IN NEURODEGENERATIVE DISORDERS, 1999, 893 : 298 - 300
  • [47] TRANSGENIC MINIATURE PIG AS AN ANIMAL MODEL FOR HUNTINGTON'S DISEASE
    Baxa, M.
    Juhas, S.
    Pavlok, A.
    Vodicka, P.
    Juhasova, J.
    Hruska-Plochan, M.
    Miyanohara, A.
    Marsala, M.
    Cattaneo, E.
    Difiglia, M.
    Motlik, J.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2010, 81 : A8 - A9
  • [48] Striatal neurochemical changes in transgenic models of Huntington's disease
    Ariano, MA
    Aronin, N
    Difiglia, M
    Tagle, DA
    Sibley, DR
    Leavitt, BR
    Hayden, MR
    Levine, MS
    JOURNAL OF NEUROSCIENCE RESEARCH, 2002, 68 (06) : 716 - 729
  • [49] Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease
    Turmaine, M
    Raza, A
    Mahal, A
    Mangiarini, L
    Bates, GP
    Davies, SW
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (14) : 8093 - 8097
  • [50] Evaluation of treatment stategies for Huntington's disease in transgenic mice
    Schiefer, J
    Lüesse, HG
    Sprünken, A
    Puls, C
    Milkereit, A
    Milkereit, E
    Kosinski, CM
    ACTA NEUROPATHOLOGICA, 2002, 104 (05) : 568 - 568